title: Interaction study between digoxin and a preparation of hawthorn (Crataegus oxyacantha).
abstract: Hawthorn, an herbal supplement, is currently being evaluated for the treatment of heart failure. The flavonoid components of hawthorn may be responsible for hawthorn's beneficial effects in the treatment of heart failure. However, these components may also affect P-glycoprotein function and cause interactions with drugs that are P-glycoprotein substrates, such as digoxin, which is also used to treat heart failure. Therefore, the purpose of this study was to determine the effect of hawthorn on digoxin pharmacokinetic parameters. A randomized, crossover trial with 8 healthy volunteers was performed evaluating digoxin 0.25 mg alone (D) for 10 days and digoxin 0.25 mg with Crataegus special extract WS 1442 (hawthorn leaves with flowers; Dr. Willmar Schwabe Pharmaceuticals) 450 mg twice daily (D + H) for 21 days. Pharmacokinetic studies were performed for 72 hours. There were no statistically significant differences in any measured pharmacokinetic parameters. The AUC0-infinity, Cmax-Cmin, Cmin, and renal clearance for the D group were 79 +/- 26 mcg.h/L, 1.4 +/- 0.7 mcg/L, 0.84 +/- 0.2 mcg/L, and 74 +/- 10 mL/min versus 73 +/- 20 mcg.h/L, 1.1 +/- 0.1 mcg/L, 0.65 +/- 0.2 mcg/L, and 81 +/- 22 mL/min for the D + H group, respectively (p > 0.05). Following 3 weeks of concomitant therapy, hawthorn did not significantly alter the pharmacokinetic parameters for digoxin. This suggests that both hawthorn and digoxin, in the doses and dosage form studied, may be coadministered safely.
authors.affiliation: University of Michigan College of Pharmacy, University of Michigan Health Systems, Ann Arbor, Michigan, USA.
authors.forename: Roberta
authors.initials: R
authors.lastname: Tankanow
authors.forename: Helen R
authors.initials: HR
authors.lastname: Tamer
authors.forename: Daniel S
authors.initials: DS
authors.lastname: Streetman
authors.forename: Scott G
authors.initials: SG
authors.lastname: Smith
authors.forename: Janice L
authors.initials: JL
authors.lastname: Welton
authors.forename: Thomas
authors.initials: T
authors.lastname: Annesley
authors.forename: Keith D
authors.initials: KD
authors.lastname: Aaronson
authors.forename: Barry E
authors.initials: BE
authors.lastname: Bleske
mesh_terms: D000328:Adult; D019540:Area Under Curve; D002316:Cardiotonic Agents / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D027825:Crataegus; D004077:Digoxin / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D004347:Drug Interactions; D005260:Female; D006207:Half-Life; D029001:Herbal Medicine; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate
chemical_list: D002316:Cardiotonic Agents; D004077:Digoxin